CNTA Form 144: Insider sale of ADRs reported

CNTA filed a Form 144 reporting proposed sales of American Depositary Receipts (ADRs).

Rhea-AI Filing Summary

CNTA filed a Form 144 reporting proposed sales of American Depositary Receipts (ADRs). The notice lists an ADR sale tied to an exercise of stock options for cash with an action date of 03/17/2026. The filing also discloses prior disposals by Karen M. Anderson on 03/13/2026 of 120,029 ADRs for $3,150,680.17 and on 03/16/2026 of 64,768 ADRs for $1,826,969.27.

Insights

Corporate Governance Analyst

Form 144 records planned ADR dispositions by an insider following option exercise.

The filing lists an ADR sale linked to an exercise of stock options for 03/17/2026, indicating a disposition event rather than a routine grant. The excerpt names Karen M. Anderson and shows two prior reported sales of ADRs on 03/13/2026 and 03/16/2026 with specific share counts and proceeds.

Cash‑flow treatment is explicit as cash for the 03/17/2026 entry. Subsequent SEC reports or Form 4/5 filings may provide additional attribution and ownership detail.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does CNTA's Form 144 report?

It reports a proposed sale of ADRs tied to an exercise of stock options dated 03/17/2026. The notice also lists prior ADR disposals by Karen M. Anderson on 03/13/2026 and 03/16/2026, with share counts and proceeds.

How many ADRs did Karen M. Anderson sell recently for CNTA?

The excerpt shows sales of 120,029 ADRs on 03/13/2026 and 64,768 ADRs on 03/16/2026. The filing ties a separate ADR sale to an option exercise dated 03/17/2026 in the same sequence of transactions.

What proceeds were reported for the recent CNTA ADR sales?

The filing lists proceeds of $3,150,680.17 for the 120,029 ADRs sale on 03/13/2026 and $1,826,969.27 for the 64,768 ADRs sale on 03/16/2026. The 03/17/2026 exercise entry shows cash as the consideration.

Does the Form 144 indicate how the 03/17/2026 ADRs will be sold?

The excerpt identifies the 03/17/2026 entry as an Exercise of Stock Options with consideration listed as cash. The filing does not provide additional distribution methods in the provided excerpt.

Is the 03/17/2026 ADR transaction an acquisition or a disposition for CNTA insiders?

The 03/17/2026 line is recorded under 'Securities To Be Sold' and is linked to an exercise of stock options, indicating the filing reports a planned or proposed disposition rather than an acquisition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 04:02 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001762176
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Centessa Pharmaceuticals plc
SEC File Number	001-40445
Address of Issuer	3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE UNITED KINGDOM WA14 2DT
Phone	44 7391 789784
Name of Person for Whose Account the Securities are To Be Sold	Anderson Karen M.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADR	UBS Financial Services Inc. 11 Madison Ave 4th Floor New York NY 10010	10043	281003.14	134447836	03/17/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADR	03/17/2026	Exercise of Stock Options	Issuer			10043	03/17/2026	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Karen M. Anderson c/o 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	ADR	03/13/2026	120029	3150680.17
Karen M. Anderson c/o 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	ADR	03/16/2026	64768	1826969.27

144: Remarks and Signature

Remarks	The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan.
Date of Notice	03/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Karen Anderson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)